HomeCompareCTAGY vs JNJ

CTAGY vs JNJ: Dividend Comparison 2026

CTAGY yields 11.70% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CTAGY wins by $12.8K in total portfolio value
10 years
CTAGY
CTAGY
● Live price
11.70%
Share price
$17.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43.3K
Annual income
$2,428.55
Full CTAGY calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — CTAGY vs JNJ

📍 CTAGY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCTAGYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CTAGY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CTAGY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CTAGY
Annual income on $10K today (after 15% tax)
$994.15/yr
After 10yr DRIP, annual income (after tax)
$2,064.27/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, JNJ beats the other by $1,973.13/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CTAGY + JNJ for your $10,000?

CTAGY: 50%JNJ: 50%
100% JNJ50/50100% CTAGY
Portfolio after 10yr
$36.9K
Annual income
$3,589.21/yr
Blended yield
9.74%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CTAGY
No analyst data
Altman Z
4.6
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CTAGY buys
0
JNJ buys
0
No recent congressional trades found for CTAGY or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCTAGYJNJ
Forward yield11.70%2.14%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$43.3K$30.5K
Annual income after 10y$2,428.55$4,749.88
Total dividends collected$17.9K$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CTAGY vs JNJ ($10,000, DRIP)

YearCTAGY PortfolioCTAGY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,870$1,169.59$10,594$274.49+$1.3KCTAGY
2$13,998$1,297.44$11,294$360.69+$2.7KCTAGY
3$16,408$1,429.98$12,133$476.91+$4.3KCTAGY
4$19,123$1,566.50$13,156$635.42+$6.0KCTAGY
5$22,168$1,706.28$14,432$854.61+$7.7KCTAGY
6$25,568$1,848.56$16,056$1,162.76+$9.5KCTAGY
7$29,350$1,992.63$18,175$1,604.53+$11.2KCTAGY
8$33,543$2,137.77$21,009$2,252.68+$12.5KCTAGY
9$38,174$2,283.29$24,911$3,229.73+$13.3KCTAGY
10$43,275$2,428.55$30,458$4,749.88+$12.8KCTAGY

CTAGY vs JNJ: Complete Analysis 2026

CTAGYStock

Capita plc provides consulting, digital, and software products and services to clients in the private and public sectors in the United Kingdom and internationally. It operates through Public Service, Experience, and Portfolio divisions. The company offers solutions for finance and accounting, procurement, property and infrastructure, travel and event, and workplace administration. It also provides customer experience transformation, contact management, collection, complaint handling, customer acquisition and retention, customer experience system and software, and data and analytics. In addition, the company offers capita licensing and support, support, digital policing, and engineering practice; education service and local education authority software; various solutions that help businesses create connected experiences that deliver right message across organisations, customers, and suppliers; solutions for central and local government services; corporate learning, fire service college, employability, and capita apprenticeship solutions; and employer branding and marketing, flexible workforce solutions, agile resourcing solutions, executive and specialist recruitment, background checking and vetting, and digital HR management and transformation solutions. Further, it provides pension administration and software, pensions consulting, and data, insights, and remediation solutions; automation, critical communication systems, finance and payment software, local education authority software, management information systems, and workforce management software solutions; cloud, cyber security, digital connectivity, IT services, robotic process automation, and workplace IT; and actuarial, defence, financial, healthcare, housing, legal, public safety, utility, and welfare and employability services. The company was formerly known as The Capita Group plc and changed its name to Capita plc in January 2012. Capita plc was founded in 1984 and is based in London, the United Kingdom.

Full CTAGY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this CTAGY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CTAGY vs SCHDCTAGY vs JEPICTAGY vs OCTAGY vs KOCTAGY vs MAINCTAGY vs ABBVCTAGY vs MRKCTAGY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.